GlassScriptPhysician profile
Leroy B Fleischer
NPI 1902809791
$4,543.69
in general payments reported to CMS, 2019-2025
26 companies · $22.91 in 2025
The $22.91 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,084 · 2020: $1,290 · 2021: $1,072 · 2022: $74.20 · 2025: $22.91.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $912.18 | 2019-2021 | |
| Lilly USA, LLC | $696.30 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $552.11 | 2019-2021 | |
| Amgen INC. | $548.28 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $497.43 | 2019-2022 | |
| Novo Nordisk INC | $324.19 | 2019-2021 | |
| Allergan, INC. | $208.56 | 2019-2020 | |
| Abbvie INC. | $184.25 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.41 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $66.05 | 2021 | |
| Merck Sharp & Dohme LLC | $48.38 | 2019-2021 | |
| Pfizer INC. | $42.21 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $34.35 | 2019-2021 | |
| Almatica Pharma LLC | $32.21 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $30.62 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $30.06 | 2021 | |
| Esperion Therapeutics, INC. | $28.29 | 2020 | |
| Jazz Pharmaceuticals INC. | $27.71 | 2021 | |
| Adlon Therapeutics L.P. | $24.76 | 2020 | |
| Exact Sciences Corporation | $22.91 | 2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $18.84 | 2019 | |
| Glaxosmithkline, LLC. | $18.20 | 2019 | |
| Aytu Biopharma, INC. | $14.15 | 2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.95 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.68 | 2020 | |
| Biogen, INC. | $13.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leroy Fleischer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.